Obsessive-Compulsive Disorder: Strategies to Maximize Opportunities in a Small Market
Decision Resources
May 7, 2008 24 Pages - SKU: DECR1785429
|
|
Although the obsessive-compulsive disorder (OCD) market is small and OCD diagnosis rates are low, this
market is characterized by substantial unmet need and commercial opportunity. Companies looking to expand
their agents into this market need to explore unconventional strategies that will minimize the resources
necessary to ensure success in OCD.
Get the Answers You Need to Shape Your Strategy
- Despite the high use of drug therapy in the treatment of OCD, 40-60% of patients do not achieve suffi cient
relief from their symptoms. What opportunities does this unmet need present to developers? Are any
agents now in development likely to meet this need?
- Due to the large percentage of patients who are not suffi ciently treated with available approved agents,
psychiatrists often prescribe off-label agents to treat OCD. How well do these off-label agents perform
in the OCD market? Will pending guidance from the FDA regarding the distribution of data from
clinical trials in off-label indications help companies increase their market share for off-label
treatments?
- Although there are few agents in commercial development for OCD, there are agents being investigated
for their effi cacy in OCD by research and medical organizations. What does the possible infl ux of a large
number of new agents to treat OCD mean for currently available treatments? How can emerging
agents differentiate themselves from other current and emerging agents?
Scope
- Overview of OCD: symptoms and diagnosis, etiology.
- Epidemiology: Decision Resources estimates of the number of prevalent cases of OCD in the major
markets over 2007-2017 and the number of diagnosed and drug-treated cases in the major markets in
2007.
- Treatment algorithms: a treatment decision tree, a listing of currently used agents, and profi les of
leading agents.
- Use of off-label agents: discussion of agents commonly used off-label, physician attitudes toward
off-label use, pending FDA proposals to broaden marketing of these agents.
- OCD market: 2007 sales fi gures, current market dynamics, strategies for maximizing market
potential.
Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Overview of Obsessive-Compulsive Disorder
- Disease Diagnosis and Symptoms
- Etiology
- Epidemiology
- Current Treatments for Obsessive-Compulsive Disorder
- Treatment Algorithm for Obsessive-Compulsive Disorder
- FDA-Approved Treatments for Obsessive-Compulsive Disorder
- Eli Lilly’s Prozac
- GlaxoSmithKline’s Paxil
- Pfi zer’s Zoloft
- Novartis’s Anafranil
- Drugs Used Off-Label to Treat Obsessive-Compulsive Disorder
- Forest Laboratories’ Lexapro
- SNRIs
- Benzodiazepines
- Atypical Antipsychotics
- 2007 U.S. Market
- Maximizing the Potential of the Obsessive-Compulsive Disorder Market
- Current Dynamics of the Obsessive-Compulsive Disorder Market
- Strategies for the Obsessive-Compulsive Disorder Market
- Pediatric Approval
- Small Clinical Trials
- Tables:
- 1. Agents Commonly Used to Treat Obsessive-Compulsive Disorder
- 2. U.S. Obsessive-Compulsive Disorder Market, 2007
- 3. Agents Approved for Other Indications Being Investigated for Effi cacy in Obsessive-Compulsive Disorder, 2008
- Figures:
- 1. Total Prevalent Cases of Obsessive-Compulsive Disorder in the United States, Europe, and Japan, 2007-2017
- 2. Diagnosed and Drug-Treated Cases of Obsessive-Compulsive Disorder in the United States, Europe, and Japan, 2007
- 3. Treatment Algorithm for Obsessive-Compulsive Disorder
- 4. SSRI Action at the Serotonergic Synapse
- 5. Market Share of Leading Companies in the U.S. Obsessive-Compulsive Disorder Market, 2007
Share this report
Other tasks Related Markets Behavioral Health Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
